# Methotrexate For The Prevention and Treatment of Proliferative Vitreoretinopathy in Pediatric Patients

> **NCT04830878** · PHASE1 · WITHDRAWN · sponsor: **Stanford University**

## Conditions studied

- Proliferative Vitreoretinopathy

## Interventions

- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT04830878
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-04
- **Primary completion:** 2023-04
- **Final completion:** 2024-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2023-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04830878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04830878, "Methotrexate For The Prevention and Treatment of Proliferative Vitreoretinopathy in Pediatric Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04830878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*